Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Kenji Fujiwara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5900-9382; OpenAlex author ID A5053341340. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2012: 2 papers · 2013: 4 papers · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 18

  1. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Co-author DOI 10.1126/sciadv.adp0684↗
  2. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Co-author DOI 10.1016/j.canlet.2023.216366↗
  3. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
  4. Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry. Co-author DOI 10.1186/s13045-022-01373-6↗
  5. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Co-author DOI 10.1038/s41392-021-00769-z↗
  6. Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-021-01203-1↗
  7. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000351↗
  8. Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer. Co-author DOI 10.1021/acs.bioconjchem.9b00161↗
  9. Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Co-author DOI 10.1158/0008-5472.can-15-3264↗
  10. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Co-author DOI 10.3892/ijo.2015.3022↗
  11. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0107247↗
  12. Peritoneal myofibroblasts at metastatic foci promote dissemination of pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2391↗
  13. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. Co-author DOI 10.1016/j.surg.2013.03.010↗
  14. Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. Co-author DOI 10.1097/mpa.0b013e318293e7bd↗
  15. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Co-author DOI 10.1158/0008-5472.can-12-3180↗
  16. S100A4 mRNA expression level is a predictor of radioresistance of pancreatic cancer cells. Co-author DOI 10.3892/or.2013.2636↗
  17. Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. Co-author DOI 10.1371/journal.pone.0040434↗
  18. CD271⁺ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells. Co-author DOI 10.1371/journal.pone.0052682↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 8 shared papers, 2016–2024 · strength 0.94
  2. Stephen T. Muth · 5 shared papers, 2020–2024 · strength 0.65
  3. Xingyi Pan · 3 shared papers, 2021–2024 · strength 0.43
  4. Keyu Li · 3 shared papers, 2020–2024 · strength 0.37
  5. Brian T. Herbst · 3 shared papers, 2020–2022 · strength 0.36
  6. Tengyi Zhang · 2 shared papers, 2022–2023 · strength 0.32
  7. Kenoki Ohuchida · 9 shared papers, 2012–2015 · strength 0.32
  8. Masao Tanaka · 9 shared papers, 2012–2015 · strength 0.32
  9. Qian Xiao · 3 shared papers, 2016–2021 · strength 0.31
  10. Sophia Y. Chen · 2 shared papers, 2022–2023 · strength 0.28
  11. Jianxin Wang · 2 shared papers, 2022–2023 · strength 0.28
  12. Takao Ohtsuka · 8 shared papers, 2012–2015 · strength 0.28
  13. Nan Niu · 2 shared papers, 2022 · strength 0.27
  14. Lin Cui · 6 shared papers, 2013–2015 · strength 0.22
  15. Elizabeth M. Jaffee · 2 shared papers, 2016–2024 · strength 0.22
  16. Noelle R. Jurcak · 2 shared papers, 2020–2021 · strength 0.21
  17. Ding Ding · 2 shared papers, 2020–2022 · strength 0.20
  18. May Tun Saung · 2 shared papers, 2020–2022 · strength 0.20
  19. Daiki Eguchi · 6 shared papers, 2012–2014 · strength 0.20
  20. Shingo Kozono · 6 shared papers, 2012–2014 · strength 0.20
  21. Naoki Ikenaga · 6 shared papers, 2012–2014 · strength 0.20
  22. Koji Shindo · 5 shared papers, 2012–2015 · strength 0.18
  23. Wei‐Chih Sun · 1 shared paper, 2024 · strength 0.17
  24. Selina Shiqing K. Teh · 1 shared paper, 2024 · strength 0.17
  25. Noelle R. J. Thielman · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.